For patients with follicular lymphoma or diffuse large B-cell lymphoma, the treatment options just grew by one. On August 15, 2024, the European Union approved Odronextamab, a drug built on a relatively new kind of biology. It is a CD20 x CD3 bispecific monoclonal antibody, sold as Ordspono. Regeneron Pharmaceuticals developed it.
This is not a small tweak to an existing therapy. Bispecific antibodies are designed to grab two different targets at once. Odronextamab binds to CD20 on cancerous B-cells and to CD3 on immune T-cells. The idea is to force the immune system to do what it often fails to do on its own: recognize and kill lymphoma cells. That dual mechanism is what sets it apart from standard monoclonal antibodies, which typically hit only one target.
Follicular lymphoma and diffuse large B-cell lymphoma are both cancers of the immune system. They are serious. Patients can run through standard chemotherapy and targeted drugs and still relapse. Each new approval, especially one with a fresh mechanism, gives doctors another tool for those moments when the old ones stop working. The EU’s decision means European patients now have access to that tool.
The approval did not come without risk. Regeneron’s clinical data showed common side effects, and they are the kind that require careful management. Cytokine release syndrome tops the list. That is a systemic inflammatory response that can look like a severe flu or worse. Infections, neutropenia, fever, anemia, thrombocytopenia, and diarrhea were also frequent. These are not minor complaints. But they are familiar ground for oncologists, who deal with them routinely in other cancer therapies. The trade-off, for many patients, is worth it.
Regeneron has a history of pushing into difficult biology. The company is known for its work on monoclonal antibodies, including treatments for Ebola and COVID-19. Odronextamab is part of that same pipeline. The drug has been in development for years, working its way through clinical trials that measured response rates and durability. The EU approval is the result of that long, slow process. It is a regulatory milestone, but it is also a practical one. Patients now have something that did not exist before.
The broader context matters here. The field of bispecific antibodies is still young. The first such drug for cancer won approval only a few years ago. Each new entry, like Odronextamab, helps validate the entire approach. It tells researchers and investors that the mechanism works, that regulators accept it, and that patients can tolerate it. That momentum can accelerate development for other bispecifics targeting other cancers.
For now, the focus is on lymphoma. The approval gives European hematologists a new option. It does not cure everyone. No single drug does. But it adds to the arsenal. And for patients who have watched their disease return after multiple lines of therapy, another option is not a small thing. It is a chance.
